GlobeNewswire: GeneriCo, LLC Contains the last 10 of 6 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T06:29:17ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/07/17/1538416/0/en/GeneriCo-LLC-Completes-Transaction.html?f=22&fvtc=4&fvtv=27913GeneriCo, LLC Completes Transaction2018-07-17T13:49:48Z<![CDATA[ST. LOUIS, July 17, 2018 (GLOBE NEWSWIRE) -- GeneriCo, LLC (GeneriCo), a specialty generic drug company, today announced that it completed a deal transaction with a leading US generic pharmaceutical company for the development and commercialization rights for three GeneriCo generic modified release product formulations. Terms of the transaction were not disclosed.]]>https://www.globenewswire.com/news-release/2017/05/19/989201/0/en/GeneriCo-LLC-Prevails-in-Inter-Partes-Review-of-United-States-Patent-8-865-688.html?f=22&fvtc=4&fvtv=27913GeneriCo, LLC Prevails in Inter Partes Review of United States Patent 8,865,6882017-05-19T20:35:27Z<![CDATA[ST. LOUIS, May 19, 2017 (GLOBE NEWSWIRE) -- GeneriCo, LLC (GeneriCo), a global specialty generic drug company, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of its petition for Inter Partes Review (“IPR”) of the Valeant Pharmaceuticals International, Inc. U.S. Patent 8,865,688 (the ‘688 Patent).  The PTAB’s decision invalidates all of the disputed claims of the '688 Patent that previously provided Apriso® (extended-release capsules containing 0.375g mesalamine as a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adults) FDA Orange Book exclusivity through May 1, 2030.]]>https://www.globenewswire.com/news-release/2017/01/27/911695/0/en/Pharmaceuticals-Veteran-George-R-Stevenson-Joins-the-GeneriCo-Board-of-Directors.html?f=22&fvtc=4&fvtv=27913Pharmaceuticals Veteran George R. Stevenson Joins the GeneriCo Board of Directors2017-01-27T16:29:31Z<![CDATA[ST. LOUIS, Jan. 27, 2017 (GLOBE NEWSWIRE) -- GeneriCo, LLC (“GeneriCo”), a global generic specialty pharmaceutical company, is pleased to announce that George R. Stevenson has joined the Company’s Board of Directors as the new Chairman of the Board.  Mr. Stevenson brings deep generic and brand pharmaceutical expertise to the GeneriCo Board and is a seasoned pharmaceutical executive with many years of leadership in this dynamic marketplace.  Mr. Stevenson most recently served as the President and Chief Executive Officer of Kremers Urban Pharmaceuticals (Division of UCB, Inc.) which was acquired in 2015 by Lannett Company, Inc. for $1.23B.]]>https://www.globenewswire.com/news-release/2016/09/09/870670/0/en/GeneriCo-Announces-Collaboration-with-Zhejiang-Hisun-to-Launch-Generic-Pharmaceutical-Products-in-the-US.html?f=22&fvtc=4&fvtv=27913GeneriCo Announces Collaboration with Zhejiang Hisun to Launch Generic Pharmaceutical Products in the US2016-09-09T02:30:37Z<![CDATA[ST. LOUIS, Sept. 08, 2016 (GLOBE NEWSWIRE) -- GeneriCo, LLC, a global specialty generic pharmaceutical company, has announced the signing of a collaboration with Zhejiang Hisun Pharmaceutical Co, Ltd, and its affiliate Hisun Pharmaceuticals USA, whereby GeneriCo will be the exclusive sales and marketing partner for a portfolio of generic drugs developed and manufactured by Hisun for the US market. As part of the terms, subject to full final agreement, GeneriCo is planning to launch these products during 2016 and 2017.]]>https://www.globenewswire.com/news-release/2016/06/13/848079/0/en/GeneriCo-LLC-Inter-Partes-Review-of-United-States-Patent-8-865-688-Instituted.html?f=22&fvtc=4&fvtv=27913GeneriCo, LLC Inter Partes Review of United States Patent 8,865,688 Instituted2016-06-13T13:00:00Z<![CDATA[ST. LOUIS, June 13, 2016 (GLOBE NEWSWIRE) -- GeneriCo, LLC (“GeneriCo”), a global specialty generic drug company, today announced it has received a favorable institution decision for its petition for Inter Partes Review (“IPR”) of United States Patent No. 8,865,688 (“the ‘688 patent”) with the United States Patent and Trademark Office (“USPTO”).]]>https://www.globenewswire.com/news-release/2015/12/16/795781/0/en/GeneriCo-LLC-Files-for-Inter-Partes-Review-of-United-States-Patent-8-865-688.html?f=22&fvtc=4&fvtv=27913GeneriCo, LLC Files for Inter Partes Review of United States Patent 8,865,6882015-12-16T01:41:28Z<![CDATA[ST. LOUIS, Dec. 15, 2015 (GLOBE NEWSWIRE) -- GeneriCo, LLC (“GeneriCo”) today announced that it has recently filed a petition for Inter Partes Review (“IPR”) of United States Patent No. 8,865,688 (“the ‘688 patent”) with the United States Patent and Trademark Office (“USPTO”).]]>